| Outcome Measures: |
Primary: AUCIco,τ,SS, Area under the serum insulin icodec concentration-time curve during one dosing interval at steady state, pmol\*h/L, From 0 to 168 hours after trial product administration (Day 50) | Secondary: AUCGIR,0-36h,SS,Area under the glucose infusion rate-time curve at steady state, mg/kg, From 0 to 36 hours after trial product administration (Day 36)|AUCGIR,40-64h,SS,Area under the glucose infusion rate-time curve at steady state, mg/kg, From 40 to 64 hours after trial product administration (Day 43)|AUCGIR,144-168h,SS,Area under the glucose infusion rate-time curve at steady state, mg/kg, From 144 to 168 hours after trial product administration (Day 50)|AUCGIR,τ,SS,model, Model-based area under the glucose infusion rate-time curve during one dosing interval at steady state, mg/kg, From 0 to 168 hours after trial product administration (Day 50)|AUCIco,τ,SS, Area under the serum insulin icodec concentration-time curve during one dosing interval at steady state, pmol\*h/L, From 0 to 168 hours after trial product administration (Day 36 and 43)|Dose-normalised AUCIco,τ,SS, Area under the serum insulin icodec concentration-time curve during one dosing interval at steady state divided by dose, (pmol\*h/L)/(U/kg), From 0 to 168 hours after trial product administration (Day 50)|Cmax,Ico,SS, Maximum observed serum insulin icodec concentration during one dosing interval at steady state, pmol/L, From 0 to 168 hours after trial product administration (Day 36, 43 and 50)|Dose-normalised Cmax,Ico,SS, Maximum observed serum insulin icodec concentration after the last dose divided by dose, (pmol/L)/(U/kg), From 0 to 168 hours after trial product administration (Day 50)|tmax,Ico,SS, Time to maximum observed serum insulin icodec concentration after the last dose, hours, From 0 to 168 hours after trial product administration (Day 50)|t½,Ico,SS, Terminal half-life for insulin icodec at steady state, hours, Terminal part of the serum insulin icodec concentration-time curve where the curve is well approximated by a straight line on logarithmic scale after last trial product administration (Day 50)
|
